Cargando…

Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA

PURPOSE: To evaluate prostate-cancer specific mortality (PCSM) in a cohort of high-risk patients treated with a permanent prostate brachytherapy approach, stratified by pre-treatment PSA. MATERIAL AND METHODS: 448 high-risk patients (NCCN criteria) underwent permanent prostate brachytherapy. High ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merrick, Gregory S., Galbreath, Robert W., Butler, Wayne M., Fiano, Ryan, Adamovich, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611460/ https://www.ncbi.nlm.nih.gov/pubmed/28951747 http://dx.doi.org/10.5114/jcb.2017.69588

Ejemplares similares

Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts
por: Merrick, Gregory S., et al.
Publicado: (2015)

Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trials
por: Merrick, Gregory S., et al.
Publicado: (2017)

Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy
por: Taira, Al V., et al.
Publicado: (2014)

The impact of age on prostate cancer progression and quality of life in active surveillance patients
por: Merrick, Gregory S., et al.
Publicado: (2020)

Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment
por: Taira, Al V., et al.
Publicado: (2013)

Permanent prostate brachytherapy extracapsular radiation dose distributions: analysis of a multi-institutional database
por: Merrick, Gregory S., et al.
Publicado: (2013)

CT-PLANNED transperineal prostate BIOPSY IN patients without a rectum
por: Merrick, Gregory S., et al.
Publicado: (2020)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Effect of the timing of hydrogel spacer placement on prostate and rectal dosimetry of low-dose-rate brachytherapy implants
por: Butler, Wayne M., et al.
Publicado: (2021)

Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
por: Galego, Pedro, et al.
Publicado: (2015)

Permanent (125)I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence
por: Mazeron, Renaud, et al.
Publicado: (2012)

Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy
por: Yamamoto, Yoichiro, et al.
Publicado: (2016)

Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
por: Taira, A V, et al.
Publicado: (2009)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators
por: Liu, Xiaomin, et al.
Publicado: (2023)

cExternal beam radiation results in minimal changes in post void residual urine volumes during the treatment of clinically localized prostate cancer
por: Orio, Peter F, et al.
Publicado: (2009)

Low‐Dose‐Rate Prostate Brachytherapy (LDR‐PB) adopts postsurgical PSA value for definition of cure
por: Uribe, Jennifer, et al.
Publicado: (2020)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions
por: Flores-Fraile, María-Carmen, et al.
Publicado: (2020)

Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity
por: Mattsson, Johanna M., et al.
Publicado: (2014)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Characterization of the Prostate-Specific Antigen (PSA) Catalytic Mechanism: A Pre-Steady-State and Steady-State Study
por: Tomao, Luigi, et al.
Publicado: (2014)

Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements
por: McJimpsey, Erica L.
Publicado: (2016)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

PROSTATE-SPECIFIC ANTIGEN (PSA) VALUES IN PATIENTS WITH LOW- AND HIGH-RISK PROSTATIC ADENOCARCINOMA
por: Mašić, Silvija, et al.
Publicado: (2019)

Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes
por: Llop, Esther, et al.
Publicado: (2016)

Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer
por: Song, Wei, et al.
Publicado: (2022)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men
por: Coric, Jozo, et al.
Publicado: (2015)

Associations of multimorbidity and patient‐reported experiences of care with conservative management among elderly patients with localized prostate cancer
por: Fiano, Ryan M., et al.
Publicado: (2020)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

Quality of life of men treated with brachytherapies for prostate cancer
por: Lev, Elise L, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_l012upcd8e2imrctlvaoi94r44